This raises the question of whether disruption of the PTIS in PTR cells should involve targeting the secretory-controlling IFN-signaling machinery or targeting ISG secretory products directly, thereby potentially avoiding disruption of IFNs anti-tumor functions. This evidence concerns the gene IFNA1 and neoplasm.